Chronic Disease Prevalence And Standardized Dialysis Popularization

The sustained growth of the global Arteriovenous Fistula Needle market is fundamentally driven by the rising prevalence of chronic kidney disease and end-stage renal disease worldwide, supplemented by the popularization of standardized hemodialysis treatment guidelines, the improvement of medical consumption capacity and the iteration of safe medical consumable technologies. Different from ordinary medical disposable supplies, AVF needles are highly dependent on professional clinical treatment scenarios, and the expansion of patient groups and the standardization of treatment modes constitute the core underlying logic of market growth.

The continuous increase in the number of global CKD and ESRD patients is the primary rigid demand driver. With the changes in modern lifestyle, aging population acceleration, and the increasing prevalence of chronic diseases such as hypertension and diabetes, the incidence of chronic kidney disease has risen year by year globally. Diabetes and hypertension are the main inducements of renal failure, and the long-term chronic damage of blood vessels will eventually lead to end-stage renal disease, requiring long-term regular hemodialysis to maintain life. Clinical data shows that more than 64% of global dialysis demand comes from long-term ESRD patients, and each patient needs repeated dialysis treatment 3-4 times a week, generating continuous and stable repetitive demand for AVF needles, forming a rigid and sustainable market demand base.

Global medical guideline iteration and standardized dialysis treatment popularization further boost market expansion. Major global medical institutions and nephrology associations have clearly defined that arteriovenous fistula is the preferred vascular access for long-term hemodialysis, due to its higher blood flow efficiency, longer service life, lower infection rate and better long-term patient prognosis compared with catheter access and artificial vascular access. In 2024, the AVF access segment occupied 71.9% of the global vascular access market share, which fully reflects the global medical community's unified recognition of AVF mode. The popularization of AVF priority treatment standards directly drives the continuous growth of supporting AVF needle demand and eliminates the market uncertainty caused by alternative access modes.

The improvement of global medical infrastructure and popularization of grassroots dialysis services are important incremental drivers. In the past, high-quality hemodialysis services were mainly concentrated in tertiary hospitals and professional dialysis centers in developed regions. In recent years, emerging economies have accelerated the construction of grassroots medical facilities, continuously improved the coverage of nephrology treatment and dialysis services, and realized the sinking of hemodialysis medical resources. The expansion of dialysis service coverage enables more CKD patients to obtain standardized treatment, effectively releases incremental market demand for AVF needles, and promotes the rapid growth of the Asia-Pacific, Latin America and other emerging markets.

Patient quality of life improvement needs and medical safety upgrading requirements accelerate product replacement and iteration. Traditional ordinary puncture needles have problems such as large puncture pain, unstable fixation and high complication risk, which are easy to cause hematoma, needle displacement, vascular injury and infection, affecting patient treatment experience and fistula patency. With the improvement of global medical consumption levels, patients and medical institutions have higher requirements for dialysis comfort and safety. Low-pain siliconized needles, safety anti-puncture AVF needles and fixed wing-style high-stability products have gradually become mainstream, driving the upgrading of the stock market and further expanding the market scale.

In addition, the improvement of medical insurance policies in various countries reduces the threshold of patient treatment and guarantees continuous market demand. Most countries have included hemodialysis and supporting medical consumables in medical insurance reimbursement scope, reducing the economic pressure of long-term dialysis for patients, ensuring the continuity of patient treatment, and avoiding market demand shrinkage caused by economic factors. Under the superposition of multiple factors such as rigid patient demand, guideline standardization, infrastructure improvement and consumption upgrading, the AVF needle market will maintain stable growth in the long term.